Matricelf Ltd
Prices may be delayed up to 15 min. Not investment advice. News volume: articles about it in the 4Search index. Click a dot on the chart for the event and the news of that day.
Key statistics
Against its peers
Compare in full ›| MTLF.TA | OPHI | OCC.AX | NGEN | CNXU | CELU | |
|---|---|---|---|---|---|---|
| Market cap | 85.96M | 9.63M | 155.26M | 198.55M | 47.79M | 15.02M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | — | -24.3 | -5.4 | -2.9 | -0.8 |
| Price/book | 4.6 | 1.5 | 4.5 | 6.4 | 7.2 | -0.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −53.63% | −85.54% | −48.60% | −32.39% | −84.09% | −73.26% |
| Today | +6.13% | −2.49% | +3.64% | −3.91% | −25.48% | −1.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All MTLF.TA news ›Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones
Jul 09, 2026, 07:00 ET The collected blood samples will be used to generate induced pluripotent stem cells (iPSCs), which are intended to serve as the cellular component of Matricelf's personalized autologous neural implant. The approval…
Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury
Jun 22, 2026, 07:00 ET The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA) and is intended to serve as an IND enabling efficacy study. The program…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- prnewswire.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.